Hepatitis C treatment in the new DAA era: frontline implications | CATIE - Canada's source for HIV and hepatitis C information

Hepatitis C treatment in the new DAA era: frontline implications

Event Date: 
29 June 2018, 13:00 EDT

New direct-acting antiviral (DAA) treatments for hepatitis C are radically changing the landscape of frontline work. We now know that:

  • New treatments are highly effective, curing more than 90% of people.
  • Treatment is easier than ever before: for most people, treatment means taking their medication once per day for a few months, with mild side effects.
  • There are treatment options for people who were previously considered ‘difficult to treat’, including people who have taken treatment before but were not cured, people who are co-infected with HIV and people with chronic kidney disease.
  • There are more opportunities for novel treatment models and linkage to care for people who use drugs.

This webinar will provide an overview of hepatitis C treatments, what to expect when your clients are on treatment and what this new era of hepatitis C treatment means for frontline practice.

Moderator: Rivka Kushner, Knowledge Specialist, Hepatitis C

Speakers:

  • Dr. Hemant Shah, Clinical Practice Director, Francis Family Liver Clinic; Assistant Professor, University of Toronto, Toronto
  • Rachael Edwards, CAMPP Coordinator, Hepatitis Nurse Specialist, CUPS, Calgary
  • Lisa Toner, Community Outreach Coordinator, Réseau ACCESS Network, Sudbury
  • Elaine Polflit, Chief Administrator, SIS program, CIUSSS Centre-Sud-de-L'Île-de-Montréal, Montréal
Powerpoint/PDF File: 

Do you work in HIV or hep C?
Complete a short survey to evaluate CATIE and enter a draw to win a $250 gift card.